Arvinas to Participate in Upcoming Investor Conferences
June 05, 2023 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., June 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit
October 26, 2022 07:00 ET
|
Nurix Therapeutics, Inc.
Complete response observed and ongoing in a patient with multiply relapsed/refractory diffuse large B cell lymphoma (DLBCL) Dual BTK degradation and immunomodulatory activity achieved by day 8 and...
Global Targeted Protein Degradation (TPD) Market Research Report 2022
April 11, 2022 04:18 ET
|
Research and Markets
Dublin, April 11, 2022 (GLOBE NEWSWIRE) -- The "Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: An Industry Landscape Analysis of Stakeholders, Technologies,...
Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results
March 10, 2022 16:05 ET
|
Salarius Pharmaceuticals, Inc.
Strategic acquisition of SP-3164, a targeted protein degrader in development for hematologic and solid tumors, adds to pipeline of cancer therapies Clinical development of seclidemstat is continuing...
Salarius Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results and Highlight Recent Company Progress
March 03, 2022 07:31 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, March 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new...
Global Targeted Protein Degradation Market (2021 to 2030) - by Type of Protein Degrader, Therapeutic Areas, Route of Administration, Key Contributing Technologies and Key Geographies
July 13, 2021 05:18 ET
|
Research and Markets
Dublin, July 13, 2021 (GLOBE NEWSWIRE) -- The "Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics: Distribution by Type of Protein degrader, Therapeutic Areas, Route...
The targeted protein degradation enabling technologies market, featuring a healthy pipeline of novel therapeutics, is anticipated to be worth over USD 3.3 billion by 2030, predicts Roots Analysis
May 04, 2021 10:00 ET
|
Roots Analysis
London, May 04, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Targeted Protein Degradation Market, 2021-2030” report to its list of offerings. Small-molecule-induced...
UPPTHERA and ComInnex sign research collaboration for the development of novel Proteolysis-Targeting Chimera candidates
May 04, 2021 10:00 ET
|
Custom Chemistry Research
BUDAPEST, Hungary and SEOUL, South Korea, May 04, 2021 (GLOBE NEWSWIRE) -- UPPTHERA, a pharmaceutical venture company aiming for new drugs based on targeted protein degradation (TPD) technology and...
4 Report Package: "Drug the Undruggable" Technologies Bundle - Four Full Reports for the Price of Two
March 12, 2021 04:13 ET
|
Research and Markets
Dublin, March 12, 2021 (GLOBE NEWSWIRE) -- The "Report Package: "Drug the Undruggable" Technologies" report has been added to ResearchAndMarkets.com's offering. This report package includes four...